Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-Asparagine Synthetase (ASNS) messenger RNAs with partial complementarity to the siRNA seed region refer to a group of unintended transcripts that are downregulated during the use of RNA interference (RNAi) directed at Asparagine Synthetase. This off-target effect is primarily mediated by the 'seed region' of the siRNA (nucleotides 2 through 8), which can bind to the 3' untranslated regions (UTRs) of various mRNAs that share partial sequence complementarity (Jackson et al., 2003, Nature Biotechnology). This interaction mimics the natural regulatory mechanism of microRNAs, leading to the degradation or translational repression of these non-target genes (Birmingham et al., 2006, Nature Methods). In therapeutic contexts, such as the development of ASNS inhibitors for asparagine-dependent cancers, these off-target effects can lead to significant cellular toxicity and complicate the interpretation of phenotypic outcomes (Fedorov et al., 2006, RNA). Identifying these transcripts is crucial for the design of highly specific siRNAs, often involving chemical modifications like 2'-O-methyl groups to the seed region to reduce unintended binding. Consequently, these mRNAs are monitored as a safety concern rather than being therapeutic targets themselves.
RNA interference (RNAi) mediated degradation or translational repression through seed-region complementarity, mimicking microRNA-like regulation (Jackson et al., 2003, Nature Biotechnology).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-Asparagine Synthetase (ASNS) messenger RNAs with partial complementarity to the siRNA seed region (Off-target mRNAs).